Gubra partner Hemab Therapeutics doses first volunteer in HMB-003 Phase 1
Gubra said Hemab Therapeutics dosed the first healthy volunteer in a randomized, placebo-controlled Phase 1 trial of HMB-003, a peptide-based plasmin inhibitor for heavy menstrual bleeding.
Gubra A/S said partner Hemab Therapeutics has dosed the first healthy volunteer in a randomized, placebo-controlled Phase 1 trial of HMB-003, a peptide-based plasmin inhibitor being developed for heavy menstrual bleeding.